FIG E1. Median laboratory, clinical, and cumulative scores versus decision to start immunoglobulin *(Ig)* therapy.

TABLE E1. Initial laboratory and clinical history data of 65 patients

	Total (n = 65)
Laboratory findings on initial evaluation	
Median IgG (mg/dL), IQR (25% to 75%)	370 (190-565)
Median IgA (mg/dL), IQR (25% to 75%)	28 (12-52)
Median IgM (mg/dL), IQR (25% to 75%)	30 (12-59)
No. of subjects with protective antibody titers for either tetanus or diphtheria	38
Median protective pneumococcal serotypes after vaccination	14.3%
Clinical findings on initial evaluation (no. of subjects with:)	
History of upper respiratory tract infections ≥3/y	40
≥1 Hospitalization for related issues/5 y	28
≥5 or prophylactic antibiotic courses/y	30
History of autoimmune disease (ITP or AIHA)	12
≥3 Episodes of PNA/lifetime	11
Splenomegaly or previous splenectomy	7
Significant lymphadenopathy	5
History of sepsis/meningitis/osteomyelitis/empyema/ septic arthritis	4
Malabsorption, inflammatory bowel–like disease	3
History of diarrhea (except *Clostridium difficile*)	4
Weight loss or failure to thrive	1
Radiologic findings on initial evaluation	
PFTs with FEV$_1$/FVC ratio or TLC <70% of predicted value	1
Bronchiectasis on CT	6

AIHA, Autoimmune hemolytic anemia; *CT*, computed tomography; *FVC*, forced vital capacity; *ITP*, idiopathic thrombocytopenic purpura; *PFTs*, pulmonary function tests; *PNA*, pneumonia; *TLC*, total lung capacity.

TABLE E2. Laboratory and clinical history data of subjects according to decision to treat with immunoglobulins

	Ig recommended (n = 46)	Ig not recommended (n = 19)	*P* value
Laboratory findings on initial evaluation			
Median IgG (mg/dL), IQR (25% to 75%)	263 (159-435)	575 (458-658)	<.001*
Median IgA (mg/dL), IQR (25% to 75%)	17 (7-42)	56 (44-140)	<.001*
Median IgM (mg/dL), IQR (25% to 75%)	21 (7-38)	79 (31-107)	<.001*
No. of subjects with protective antibody titers for either tetanus or diphtheria	20	18	.0001†
Median protective pneumococcal serotypes after vaccination	7.1%	35.7%	.0034*
Clinical findings on initial evaluation (no. of subjects with:)			
History of upper respiratory tract infections ≥3/y	28	12	1.0000
≥1 Hospitalization for related issues/5 y	21	7	.5891
≥5 Prophylactic antibiotic courses/y	19	11	.2786
History of autoimmune disease (ITP or AIHA)	12	0	.0131†
≥3 Episodes of PNA/lifetime	9	2	.4857
Splenomegaly or previous splenectomy	7	0	.0960
Significant lymphadenopathy	5	0	.3104
History of sepsis/meningitis/osteomyelitis/empyema/septic arthritis	3	1	1.0000
Malabsorption, inflammatory bowel–like disease	2	1	1.0000
History of diarrhea (except *Clostridium difficile*)	1	3	.0716
Weight loss or failure to thrive	1	0	1.0000
Radiologic findings on initial evaluation			
PFTs with FEV_1/FVC ratio or TLC <70% of predicted value	1	0	1.0000
Bronchiectasis on CT	6	0	.1688

AIHA, Autoimmune hemolytic anemia; *CT*, computed tomography; *FVC*, forced vital capacity; *Ig*, immunoglobulin; *ITP*, idiopathic thrombocytopenic purpura; *PFTs*, pulmonary function tests; *PNA*, pneumonia; *TLC*, total lung capacity.

*Significant as per the Mann-Whitney *U* test.

†Significant as per the Fisher exact test.